Contact
Please use this form to send email to PR contact of this press release:
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
TO:
Please use this form to send email to PR contact of this press release:
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
TO: